Insurance coverage

CureApp: Digital Hypertension Therapy App Gets Insurance Coverage, Service Sales to Medical Institutions Across Japan to Launch on September 1

TOKYO–()–CureApp, Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Kohta Satake) announces the start of insurance coverage for its CureApp HT adjunctive hypertension treatment app (hereinafter, CureApp HT), a DTx*1 solution treating hypertension, in Japan from September 1, 2022. In the future, the app will be prescribed and provided to patients with hypertension as a health insurance treatment in medical institutions.

After confirming the efficacy and safety of CureApp HT through clinical trials, the results of a Phase III Japanese nationwide multicenter randomized controlled trial have been published in EHJ, one of the most respected peer-reviewed journals in the world in 2021. In April 2022, CureApp HT was the first digital hypertension therapy app to receive government approval worldwide, and the app has been covered by insurance since September 1. This is the first case of an insurance-covered DTx treatment solution for hypertension in the world. Looking ahead, CureApp is looking to continue its efforts to bring this Japanese-led medical innovation to market. The impact of hypertension is visible beyond Japan’s borders, and efforts to correct patients’ lifestyle habits are a common theme across the world. Therefore, CureApp also plans to proactively expand the reach of CureApp HT worldwide, starting with the United States.

Importance of lifestyle changes, current challenges and potential of CureAppHT

The 2019 Guidelines for the Management of Hypertension describe that “lifestyle changes are important because not only should they produce a hypotensive effect, but they also prevent hypertension”. The guidelines also state that “lifestyle counseling should be provided to all patients with hypertension, as it may increase the hypotensive effect and reduce the dosage of antihypertensive drugs.” Despite this recommendation, such behavioral therapy has been poorly adopted due to difficulties in getting patients to implement lifestyle changes on an ongoing basis and the limited time of physician consultation sessions. It is also said that a certain period of guided intervention*2 is necessary for lifestyle changes to take hold.

CureApp HT helps connect physicians and patients and promotes lifestyle changes that were previously difficult to sustain while ensuring that changed behavior is maintained in patients.

*1 Abbreviation for Digital Therapeutics. Products with pharmaceutical approval for use as medical devices.

*2 Kamioka H, ​​Nakamura Y, Yazaki T, Uebaba K, Mutoh Y, Okada S, Takahashi M. Comprehensive health education combining hot spa bathing and lifestyle education in middle-aged and elderly women: follow-up year on a randomized controlled trial of three and six month interventions. J Epidemiol. 2006 Jan;16(1):35-44. doi: 10.2188/jea.16.35. PMID: 16369107; PMCID: PMC7560544.

Summary of clinical trials for this product

About CureApp, Inc.

CureApp, Inc. is a MedTech company that conducts research and development in the creation of medical device programs, which apply advanced software technology and medical evidence to treat diseases, with the goal of manufacturing and curing them. distribute. The Company is working hard on the development of “therapeutic applications” – applications used to treat diseases – in order to be the first in Japan to establish a new health service centered on “the production of a therapeutic effect to treat diseases with the help of an application”. In August 2020, CureApp was the first to receive medical device regulatory approval for a disease treatment app in Japan in the form of a nicotine addiction treatment app, which was later reimbursed by the national health insurance in December of the same year.

Companies in which CureApp is involved

Nicotine addiction

Received medical device regulatory approval in August 2020; reimbursed by the National Health Insurance Fund and prescriptions begin in December of the same year


Received medical device regulatory approval in April 2022


(Non-alcoholic steatohepatitis)

In joint development with Sawai Group Holdings Co. /

Undergoing clinical trials with Tokyo University Hospital

Alcohol addiction

Application under development with the National Hospital Organization Kurihama Medical and Addiction Center /

Clinical trials underway at Okayama City General Medical Center, Okayama City Hospital


Treatment application for breast cancer patients currently in development with DAIICHI SANKYO COMPANY, LIMITED.

Chronic heart failure

Application under development with our partners from the YUMINO Medical Corporation

In addition to the above, we offer mobile health programs for private companies through our “ascure Smoking Cessation Program” and our “ascure Specific Health Orientation Program for Quitting of tobacco”, which are based on the knowledge acquired in the development of these digital therapies for medical institutions. These programs have been implemented in more than 230 companies and mutuals. In the future, we will seek to sequentially roll out this “Made-in-Japan Digital Health Solution” globally based on the model established in Japan.

CureApp, Inc. Company Profile


director and


Kohta Satake

Registered Address

Kodenma-Cho YS building 4th floor 12-5, Nihonbashi Kodenma-Cho, Chuo-ku, Tokyo, Japan, 103-0001

US branch

CureApp North America, Inc.

Commercial activities

Development of Software as a Medical Device (SaMD), mobile health-related services